Understanding the Therapeutic Potential of PD-1 Agonism in Inflammatory and Autoimmune Disorders

The therapeutic potential of programmed cell death-1 (PD-1) agonism is increasingly recognized as a cornerstone for restoring immune tolerance in autoimmune diseases. However, while PD-1 antagonism has revolutionized oncology, a critical knowledge gap remains regarding optimal strategies to therapeutically harness PD-1 activation. This review provides a comprehensive analysis of the mechanical and molecular requirements for inducing PD-1 signaling, addressing the current lack of a unified framework for agonistic drug development. We first delineate the fundamental biology of PD-1 signaling in maintaining peripheral tolerance. We then evaluate four primary mechanistic strategies currently under investigation: (1) receptor dimerization and clustering; (2) membrane-proximal epitope binding; (3) modulation of antibody binding affinity; and (4) Fcγ-receptor crosslinking. Each mechanism is critically assessed for its ability to mimic natural ligand-induced inhibitory signaling, alongside its inherent translational limitations. Emerging data suggest that optimal PD-1 agonism is achieved not through high-affinity binding but rather through low-affinity antibodies targeting membrane-proximal epitopes. This approach appears to preserve essential ligand-engagement dynamics and to facilitate productive Fcγ-receptor-mediated scaffolding. By surveying recent advances in clinical trials and ongoing challenges, this work serves as a vital resource for researchers and clinicians. Refinement of these agonistic strategies is essential for the development of next-generation targeted immunotherapies capable of precision immune regulation in chronic autoimmunity.